Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multimedia
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multimedia
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

Hepatitis C Disease Market: Clinical Trial, Drug Development, Clinical Viewpoints, and Drug Insights| Disease Landscape Insights

This image opens in the lightbox

News provided by

Disease Landscape Insights

12 Oct, 2023, 14:30 GMT

Share this article

Share toX

Share this article

Share toX

LONDON, Oct. 12, 2023 /PRNewswire/ -- Hepatitis C is a viral infection caused by the HVC virus. It leads to severe liver damage if not treated before its too late. According to an epidemiology study by the WHO, nearly 58 million people are living with this condition. This growing disease burden has raised concerns across various regions creating a need for hepatitis c prevention.

Hepatitis C is a dreadful liver disease that is highly contagious in nature. It can range from mild illness to a long-term infection. Hepatitis C transmission occurs through contact with infected blood, such as sharing needles or other drug paraphernalia, unprotected sex, and receiving contaminated blood transfusions or organ transplants. Early detection of this disease is crucial since it paves the way for fast Hepatitis C prognosis and treatment plans.

Disease Landscape Insights has been providing valuable disease overview and drug insights to the Hepatitis c market players. Apart from that, they are also leveraging DLI's healthcare consulting services to accelerate activities like clinical trial feasibility analysis, treatments gaps identification, product portfolio extension, and the formulation of ideal price and market access strategies.  DLI also offers new product launch services, post launch services, drug launch strategies, and product pipeline analysis services.

Price and Market Access

Hepatitis C- A silent killer

Many people affected with this ailment do not witness noticeable symptoms in the initial stage. That is why it is termed as silent killer. The HCV continues damaging the liver silently and it gets too late until the symptoms appear. Late hepatis c diagnosis results in fatalities or at least severe complications.

 The primary symptoms of this ailment are chronic fatigue, nausea, loss of appetite, vomiting, pale stools, jaundice, dark urine, and flu like symptoms, among others. It's important to note that these symptoms are not unique to hepatitis C and can be caused by various other health conditions. Furthermore, many people with hepatitis C may remain asymptomatic for years, and the infection may only be discovered through routine blood tests or when complications develop.

Learn More About the FDA NDA & BLA Approval (NME) Drugs for Hepatitis C Disease @

https://www.diseaselandscape.com/requestsample/postid/5

Diagnosis and Treatment:

This ailment is predominantly diagnosed through HCV antibody tests, HCV RNA tests, liver function tests, and liver biopsy. Early diagnosis can significantly improve health outcomes. It has to be kept in mind that once the virus completely damages the liver, there are less chances of recovery.

There is no permanent cure for this ailment. Also, as of now no effective hepatitis c vaccine has been developed. Hence, doctors streamline a treatment plan aimed at alleviating the symptoms and weaken the impact of the virus.

Hepatitis c antiviral drugs are the primary treatment for this condition. These drugs target the virus itself and have a high cure rate (often over 95%). Treatment duration and specific medications depend on various factors, including the genotype of the virus.

Some other hepatitis c medications are also prescribed to keep the symptoms like fever and fatigue at bay. Government bodies and pharma organizations have also joined hands to introduce affordable hepatitis c drugs so that people from weaker economic backgrounds do not stay deprived of the essential treatment.

Unlock the Benefits Today! Get Started Now and Elevate Your Experience @

https://www.diseaselandscape.com/checkout?report_id=5

Summing Up:

Hepatitis C is a viral infection that primarily affects the liver and can lead to serious liver-related health issues. Some common symptoms include flu-like symptoms, jaundice (yellowing of the skin and eyes), abdominal pain, dark urine, pale stools, loss of appetite, nausea, vomiting, and chronic fatigue. DLI has been empowering the players with a holistic approach that spans clinical research, drug development, commercial strategy analysis, and product launch services. This comprehensive approach is vital in improving the management and treatment of hepatitis C, ultimately benefiting individuals affected by the disease and public health as a whole.

Browse Through More Infectious Diseases Research Reports.

Related Reports:

Navigating Solid Tumor Diseases: Insights and Consulting Services

Demodex Blepharitis: Unveiling Insights and Consulting Services

Unveiling Hope: Navigating Duchenne Muscular Dystrophy (DMD)

Effective Psoriasis Disease Management Techniques: Unlocking Relief

Advancing research into Parkinson's Disease Global Perspectives and Innovations in Care

Unlocking the Most Recent Advances in Alzheimer's Disease research: a glimmer of hope

Global Insights on Multiple System Atrophy (MSA) Disease: Rising Against the Odds

Understanding Crohn's Disease: Its Causes, Signs, and Treatment

Predictive Analytics Powered by AI: Unlocking Insights for the Future of Healthcare

Natural Language Processing (NLP) in Healthcare: Unlocking the Potential

Posluma: A Targeted Oncology Breakthrough in Prostate Cancer Imaging

Fezolinetant by Veozah: Advancing Women's Health by Astellas Pharma Inc.

A Hopeful Sign for Migraine Sufferers: Zavzpret

Rethinking Treatment Options for a Better Future with Hemophilia Gene Therapy

Case Study: Clinical Trials for Parkinson's Disease Project Management

Case Study: The Pancreatic Cancer Treatment Landscape is Changing

Case Study: Examining Topical Medicines for Treatment of Psoriasis

Case Study: The Benefits of an Combination for Alzheimer's Drug

Case Study: Vaccine Development

A case study involving the cooperation of a pharmaceutical business with CDMOs and SMOs

About Disease Landscape:

Disease Landscape, a pioneering company specializing in Disease Intelligence, Pricing, and Market Access. Utilizing the power of data analytics, Disease Landscape Insights is dedicated to healthcare sector with invaluable, finely crafted insights and recommendations regarding global pricing and market access strategies. As a specialized firm, we are committed to delivering unparalleled insights into pricing and market access, custom-tailored to the healthcare and pharmaceutical industries. Our data-driven solutions and cutting-edge technology position us as your trustworthy partner, offering swift, adaptable, and evidence-based alternatives to traditional market access and pricing research methods.

Our core competencies encompass Market Research Services, Consulting Services, Global Pricing and Market Access, Epidemiology Studies, as well as Product Portfolio and Pipeline Services. Our expertise lies in furnishing comprehensive data intelligence throughout every phase of drug and device research.  

Contact Us:
Disease Landscape Insights LLP
6th Floor, Sr No.207, Office A H 6070 Phase 1
Solitaire Business Hub, Viman Nagar
Pune, Maharashtra, 411014
Sales Contact: +44-2038074155
Asia Office Contact: +917447409162
Email: ajay@diseaselandscape.com
Email: vishal@diseaselandscape.com
Blog: https://www.diseaselandscape.com/blogs
Case Study: https://www.diseaselandscape.com/casestudies
Pharma consulting Services
Follow Us: LinkedIn | Twitter | Facebook

Logo - https://mma.prnewswire.com/media/2217060/4328675/Disease_Landscape_Insights_Logo.jpg

Modal title

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.